Trials / Completed
CompletedNCT04943159
Afamelanotide in Patients Suffering With Acne Vulgaris
A Phase II, Randomised, Open Label Pilot Study to Evaluate the Efficacy and Safety of Two Dosage Regimens of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Mild to Moderate Acne Vulgaris
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Clinuvel Pharmaceuticals Limited · Industry
- Sex
- Male
- Age
- 18 Years – 30 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the effect of afamelanotide on the facial inflammatory acne-related lesions in patients with mild to moderate acne vulgaris, including tolerability of afamelanotide by patients with moderate acne vulgaris and effects of the treatment on quality of life in eligible patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afamelanotide | Group A is administered afamelanotide implant on Days 0, 21 and 42; Group B is administered afamelanotide implant on Days 0 and 28. |
Timeline
- Start date
- 2010-08-24
- Primary completion
- 2011-03-08
- Completion
- 2011-03-08
- First posted
- 2021-06-29
- Last updated
- 2021-10-26
- Results posted
- 2021-10-26
Source: ClinicalTrials.gov record NCT04943159. Inclusion in this directory is not an endorsement.